ISOLATED HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES AND METHODS AND KITS FOR DETECTING HUMAN AUTOANTIBODIES TO NATRIURETIC PEPTIDES

• US 20090286256A1
• Filed: 07/22/2008
• Published: 11/19/2009
• Est. Priority Date: 05/19/2008
• Status: Abandoned Application

• Current Assignee: Abbott Laboratories Incorporated
• Original Assignee: Abbott Laboratories Incorporated
• Inventors: Adamczyk, Maciej, Mattingly, Phillip G., Brashear, Roy Jeffrey
• Application Number:
  US12/177,584
• Publication Number:
  US 20090286256A1
• Time in Patent Office: Days
• US Class Current: 435/7.100
• CPC Class Codes: G01N 2333/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin G01N2333/665, corticotropin G01N2333/695
• CPC Class Codes: G01N 2333/58 Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
• CPC Class Codes: G01N 2800/32 Cardiovascular disorders
• CPC Class Codes: G01N 2800/324 Coronary artery diseases, e.g. angina pectoris, myocardial infarction
• CPC Class Codes: G01N 2800/325 Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
• CPC Class Codes: G01N 33/74 involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

The present disclosure relates to isolated human autoantibodies and assays and kits for detecting human autoantibodies reactive with at least one natriuretic peptide or natriuretic peptide fragment in a test sample.

Claims

1. A method for detecting one or more autoantibodies reactive with at least one natriuretic peptide or natriuretic peptide fragment in a test sample, the method comprising the steps of:

(a) preparing a mixture comprising a test sample being assessed for the presence of one or more autoantibodies to at least one natriuretic peptide or natriuretic peptide fragment, and a first specific binding partner labeled with a detectable label, wherein the first specific binding partner is a natriuretic peptide or a natriuretic peptide fragment and further wherein the one or more autoantibodies and the first specific binding partner form a first specific binding partner-autoantibody complex; and

(b) measuring the signal generated by or emitted from the detectable label.

2. The method of claim 1, wherein the natriuretic peptide is a pre-pro peptide precursor of human ANP, a pro peptide of human ANP, a N-terminal pro peptide of ANP, human ANP, a pre-pro peptide precursor of human BNP, a pro peptide of human BNP, a N-terminal pro peptide of BNP, human BNP, human CNP, a pro peptide of human CNP, Dendroaspis natriuretic peptide, a natriuretic peptide fragment, or any combinations thereof.

3. The method of claim 1, wherein the detectable label is an acridinium compound.

4. The method of claim 1, wherein the acridinium compound:

(a) is an acridinium-9-carboxamide having a structure according to formula I;

5. The method of claim 3, wherein the method further comprises the steps of:

generating in or providing to the mixture a source of hydrogen peroxide before or after the addition of the first specific binding partner in step (a);

adding a basic solution to the mixture to generate a light signal; and

measuring the signal in step (b) by measuring the light generated to detect the one or more autoantibodies.

6. The method of claim 1, wherein the method relates the amount of signal in step (b) to the amount of the one or more autoantibodies in the test sample either by use of a standard curve for the analyte, or by comparison to a reference standard.

7. The method of claim 1, wherein the method is adapted for use in an automated system or semi-automated system.

8. A method for detecting one or more autoantibodies reactive with at least one natriuretic peptide or natriuretic peptide fragment in a test sample, the method comprising the steps of:

(a) preparing a mixture comprising a test sample being assessed for the presence of one or more autoantibodies to at least one natriuretic peptide or natriuretic peptide fragment and a first specific binding partner that is immobilized on a solid phase, wherein the first specific binding partner is a natriuretic peptide or a natriuretic peptide fragment and further wherein the one or more autoantibodies and the first specific binding partner form a solid phase first specific binding partner-autoantibody complex;

(b) adding a second specific binding partner labeled with a detectable label to the mixture to form a first specific binding partner-one or more autoantibodies-second specific binding partner complex, wherein the second specific binding partner is an anti-human antibody; and

(c) measuring the signal generated by or emitted from the detectable label.

9. The method of claim 8, wherein said method further comprises an additional step selected from the group consisting of:

(1) removing any unbound one or more autoantibodies from the solid phase first specific binding partner-autoantibody complex prior to step (b); and

(2) removing any unbound second specific binding partner labeled with a detectable label from the first specific binding partner-one or more autoantibodies-second specific binding partner complex prior to step (c).

10. The method of claim 8, wherein the natriuretic peptide is a pre-pro peptide precursor of human ANP, a pro peptide of human ANP, a N-terminal pro peptide of ANP, human ANP, a pre-pro peptide precursor of human BNP, a pro peptide of human BNP, a N-terminal pro peptide of BNP, human BNP, human CNP, a pro peptide of human CNP, Dendroaspis natriuretic peptide, a natriuretic peptide fragment or any combinations thereof.

11. The method of claim 8, wherein the detectable label is an acridinium compound.

12. The method of claim 11, wherein the acridinium compound:

(a) is an acridinium-9-carboxamide having a structure according to formula I;

13. The method of claim 8, wherein the method further comprises the steps of:

(i) generating in or providing to the mixture a source of hydrogen peroxide before or after the addition of the second specific binding partner containing the detectable label in step (b);

(ii) after step (b) and before step (c), adding a basic solution to the mixture to generate a light signal; and

(iii) measuring the signal in step (c) by measuring the light generated to detect the one or more autoantibodies.

14. The method of claim 8, wherein the method relates the amount of signal in step (c) to the amount of the one or more autoantibodies in the test sample either by use of a standard curve for the analyte, or by comparison to a reference standard.

15. A kit for detecting one or more autoantibodies reactive with at least one natriuretic peptide or a natriuretic peptide fragment in a test sample, the kit comprising:

(a) at least one natriuretic peptide or natriuretic peptide fragment;

(b) at least one detectable label; and

(c) instructions for detecting said one or more autoantibodies.

16. The kit of claim 15, further comprising at least one anti-human antibody.

17. The kit of claim 15, wherein the natriuretic peptide is a pre-pro peptide precursor of human ANP, a pro peptide of human ANP, a N-terminal pro peptide of ANP, human ANP, a pre-pro peptide precursor of human BNP, a pro peptide of human BNP, a N-terminal pro peptide of BNP, human BNP, human CNP, a pro peptide of human CNP, Dendroaspis natriuretic peptide, a natriuretic peptide fragment, or any combinations thereof.

18. The kit of claim 15, wherein the detectable label is an acridinium compound.

19. The kit of claim 18, wherein the acridinium compound is:

(a) an acridinium-9-carboxamide having a structure according to formula I;

20. The kit of claim 18, wherein the kit further comprises:

(d) at least one basic solution; and

(e) a source of hydrogen peroxide, wherein said source contains a predetermined amount of hydrogen peroxide.

21. The kit of claim 20, wherein the kit further comprises at least one anti-human antibody.

22. An isolated human natriuretic peptide autoantibody, wherein the autoantibody is obtained by a process comprising the steps of:

(a) preparing a mixture comprising a human natriuretic peptide autoantibody; and

(b) isolating the human natriuretic peptide autoantibody from the mixture.

23. The antibody of claim 22, wherein the antibody is an IgG antibody.

24. The antibody of claim 22, wherein the antibody is an isolated human autoantibody selected from the group consisting of:

a pre-pro peptide precursor of human BNP autoantibody, a pro peptide of human BNP autoantibody, a N-terminal pro peptide of BNP autoantibody and a human BNP autoantibody.

25. The antibody of claim 22, wherein the antibody is an isolated pro peptide human BNP autoantibody.

26. A method of screening for at least one agent useful in inhibiting the binding of at least one human natriuretic peptide or natriuretic peptide fragment to at least one human natriuretic peptide autoantibody, the method comprising the steps of:

(a) preparing a mixture comprising an isolated human natriuretic peptide autoantibody;

(b) adding to the mixture at least one human natriuretic peptide or natriuretic peptide fragment and at least one agent to be tested; and

(c) determining whether the agent inhibits the binding of the at least one human natriuretic peptide or natriuretic peptide fragment to the human natriuretic peptide autoantibody.

27. A method of determining the reliability of a human natriuretic peptide assay result, the method comprising the steps of:

(a) assaying a test sample for one or more autoantibodies reactive with a human natriuretic peptide; and

(b) determining the reliability of a human natriuretic peptide assay result, wherein the presence of an elevated level in the test sample of one or more autoantibodies reactive with a human natriuretic peptide indicates that the human natriuretic peptide result is not reliable.

28. A method of assessing whether a subject has or is at risk of developing cardiovascular disease, the method comprising the steps of:

(a) determining the concentration or amount in a test sample from a subject of one or more autoantibodies reactive with human natriuretic peptide; and

(b) comparing the concentration or amount of the one or more autoantibodies reactive with human natriuretic peptide determined in step (a) with a predetermined level, wherein if the concentration or amount of the one or more autoantibodies reactive with human natriuretic peptide determined in step (a) is favorable with respect to a predetermined level, then the subject is determined not to have or be at risk for a cardiovascular disease; and

further wherein if the concentration or amount of the one or more autoantibodies reactive with human natriuretic peptide determined in step (a) is unfavorable with respect to the predetermined level then the subject is determined to have or be at risk for a cardiovascular disease.

29. The method of claim 28, wherein the human natriuretic peptide is a pre-pro peptide precursor of human ANP, a pro peptide of human ANP, a N-terminal pro peptide of ANP, human ANP, a pre-pro peptide precursor of human BNP, a pro peptide of human BNP, a N-terminal pro peptide of BNP, human BNP, human CNP, a pro peptide of human CNP or any combinations thereof.

30. A method of monitoring the progression of disease in a subject, the method comprising the steps of:

(a) determining the concentration or amount in a first test sample from a subject of one or more autoantibodies reactive with human natriuretic peptide;

(b) determining the concentration or amount in a second or subsequent test sample from the subject of one or more autoantibodies reactive with human natriuretic peptide; and

(c) comparing the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (b) with the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (a),

wherein if the concentration or amount determined in step (b) is unchanged or is unfavorable when compared to the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (a), then the disease in the subject is determined to have continued, progressed or worsened,

further wherein, if the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (b) is favorable when compared to the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (a), then the disease in the subject is determined to have discontinued, regressed or improved.

31. The method of claim 30, wherein said method further comprises comparing the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (b) or step (d) with a predetermined level.

32. The method of claim 30, wherein said method further comprises treating the subject with one or more pharmaceutical compositions for a period of time if the comparison shows that the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (b) or step (d) is unfavorably altered with respect to the predetermined level.

33. A method of monitoring the treatment of disease in a subject, the method comprising the steps of:

(a) determining the concentration or amount in a first test sample from a subject of one or more autoantibodies reactive with human natriuretic peptide;

(b) treating the subject with one or more pharmaceutical compositions for a period of time;

(c) determining the concentration or amount in a second or subsequent test sample obtained from the subject following treatment in step (b) of one or more autoantibodies reactive with human natriuretic peptide; and

(d) comparing the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (c) with the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (a),

wherein if the concentration or amount determined in step (c) is unchanged or is unfavorable when compared to the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (a), then the subject should be treated with a higher concentration of the one or more pharmaceutical compositions administered to the subject in step (b) or the subject should be treated with one or more pharmaceutical compositions that are different then the one or more pharmaceutical compositions administered to the subject in step (b).

further wherein, if the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (c) is favorable when compared to the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (a), then the subject should continue to be administered the one or pharmaceutical compositions of step (b).

34. The method of claim 33, wherein said method further comprises comparing the concentration or amount of one or more autoantibodies reactive with human natriuretic peptide determined in step (a) or step (c) with a predetermined level.